454 related articles for article (PubMed ID: 30967646)
1. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.
Bai X; Fisher DE; Flaherty KT
Nat Rev Clin Oncol; 2019 Sep; 16(9):549-562. PubMed ID: 30967646
[TBL] [Abstract][Full Text] [Related]
2. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
3. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
4. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas.
Giuliano S; Cheli Y; Ohanna M; Bonet C; Beuret L; Bille K; Loubat A; Hofman V; Hofman P; Ponzio G; Bahadoran P; Ballotti R; Bertolotto C
Cancer Res; 2010 May; 70(9):3813-22. PubMed ID: 20388797
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
6. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells.
Bourseguin J; Bonet C; Renaud E; Pandiani C; Boncompagni M; Giuliano S; Pawlikowska P; Karmous-Benailly H; Ballotti R; Rosselli F; Bertolotto C
Sci Rep; 2016 Nov; 6():36539. PubMed ID: 27827420
[TBL] [Abstract][Full Text] [Related]
7. Pathways from senescence to melanoma: focus on MITF sumoylation.
Leclerc J; Ballotti R; Bertolotto C
Oncogene; 2017 Nov; 36(48):6659-6667. PubMed ID: 28825724
[TBL] [Abstract][Full Text] [Related]
8. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
9. [The Importance of MITF Signaling Pathway in the Regulation of Proliferation and Invasiveness of Malignant Melanoma].
Urban P; Rabajdová M; Veliká B; Špaková I; Bolerázska B; Mareková M
Klin Onkol; 2016; 29(5):347-350. PubMed ID: 27739313
[TBL] [Abstract][Full Text] [Related]
10. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
11. Negative Regulatory Loop between Microphthalmia-Associated Transcription Factor (MITF) and Notch Signaling.
Golan T; Levy C
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699982
[TBL] [Abstract][Full Text] [Related]
12. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
[TBL] [Abstract][Full Text] [Related]
13. MITF, the Janus transcription factor of melanoma.
Koludrovic D; Davidson I
Future Oncol; 2013 Feb; 9(2):235-44. PubMed ID: 23414473
[TBL] [Abstract][Full Text] [Related]
14. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma.
Keenen B; Qi H; Saladi SV; Yeung M; de la Serna IL
Oncogene; 2010 Jan; 29(1):81-92. PubMed ID: 19784067
[TBL] [Abstract][Full Text] [Related]
16. The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Ballotti R; Cheli Y; Bertolotto C
Mol Cancer; 2020 Dec; 19(1):170. PubMed ID: 33276788
[TBL] [Abstract][Full Text] [Related]
17. Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.
Hertzman Johansson C; Azimi A; Frostvik Stolt M; Shojaee S; Wiberg H; Grafström E; Hansson J; Egyházi Brage S
Melanoma Res; 2013 Oct; 23(5):360-5. PubMed ID: 23921446
[TBL] [Abstract][Full Text] [Related]
18. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
19. MITF in melanoma: mechanisms behind its expression and activity.
Hartman ML; Czyz M
Cell Mol Life Sci; 2015 Apr; 72(7):1249-60. PubMed ID: 25433395
[TBL] [Abstract][Full Text] [Related]
20. Hinokitiol-induced decreases of tyrosinase and microphthalmia-associated transcription factor are mediated by the endoplasmic reticulum-associated degradation pathway in human melanoma cells.
Oyama T; Ogawa H; Shirai Y; Abe H; Kamiya T; Abe T; Tanuma SI
Biochimie; 2022 Jan; 192():13-21. PubMed ID: 34536557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
